Prabhudas Lilladher's research report on Max Healthcare Institute
Max Healthcare Institute (MAXHEALT) reported EBIDTA of Rs4.3bn (up 6% QoQ) came 4% above our estimates, aided by higher ARPOB of Rs.74.8k in Q1 vs Rs.70.7k in Q4. The company showed phenomenal growth in past two years and we expect this momentum to continue given 1) strong expansion plans (+1500 additional beds by FY25E end), 2) improving payor mix (15% revenue contribution from institutional by FY25E vs 18.4% now) and 3) scale up in labs. Operational efficiency has also been commendable, especially in competitive markets like NCR.
Outlook
Our FY24E/25E EBIDTA broadly remain unchanged and expect 15% EBIDTA CAGR over FY23-25E. We ascribe 27x EV/EBIDTA (25x earlier) based on FY25E. Maintain ‘BUY’ rating with a revised target price of Rs. 610/share (earlier Rs 565/share).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
